A Phase Ib Study of Fractionated 90Y-hPAM4 with or without Gemcitabine in Patients with Metastatic Pancreatic Cancer who Received at Least Two Prior Treatments
ID Number 12-1509Principal Investigator(s)
Max W. Sung
Department(s) or Division(s)
Hematology and Medical Oncology
The main purpose of this randomized controlled treatment trial is to test the safety of different doses of 90Y-hPAM4 by itself or combined with gemcitabine (Gemzar ®), which is a standard of treatment. The study will look to see what effects, good and/or bad, it has on you and your advanced pancreatic cancer. 90Y-hPAM4 is an experimental drug that is not approved by the United States Food and Drug Administration (FDA) for use except in research studies. Some subjects will receive gemcitabine which is approved by the FDA to treat your illness. The results will be compared among the two different study drug regimens.
Recruiting Patients: Yes